[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603607":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":53,"collaborators":57,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":23,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":23,"maxAge":23,"enrollmentInfo":68,"targetDuration":23,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":36,"whyStopped":23,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"68Ga-DOTA-CCK-FS and 68Ga-DOTA-TATE PET\u002FCT imaging","For the patients with neuroendocrine neoplasm. Intravenous administration of 1.8-2.2 MBq\u002Fkg (0.05-0.06 mCi\u002Fkg) of each radiotracer within one week. For 68Ga-DOTA-CCK-FS, imaging begins 60±5 minutes post-injection to evaluate cholecystokinin receptor (CCK-R) expression, while 68Ga-DOTA-TATE scanning starts at 45-60 minutes post-injection for somatostatin receptor (SSTR) assessment, both using a time-of-flight PET\u002FCT system with low-dose CT (120 kVp, 30-50 mAs) for attenuation correction followed by whole-body PET acquisition (2-3 min\u002Fbed position). Images are reconstructed using OSEM algorithms",[12],"Diagnostic Test: 68Ga-DOTA-CCK-FS PET\u002FCT",{"label":14,"type":6,"description":15,"interventionNames":16},"68Ga-DOTA-CCK-FS and 18F-FDG PET\u002FCT imaging","For the patients with non-neuroendocrine neoplasm. 68Ga-DOTA-CCK-FS PET\u002FCT was perfomed 60±5 minutes post-injection of 1.8-2.2 MBq\u002Fkg (0.05-0.06 mCi\u002Fkg) tracer. The 18F-FDG PET\u002FCT imaging protocol requires patients to fast for at least 6 hours and maintain blood glucose levels \\\u003C150-200 mg\u002FdL prior to intravenous administration of 3.7-5.2 MBq\u002Fkg (0.1-0.14 mCi\u002Fkg) of 18F-FDG. After a 60±5 minute uptake period , imaging is performed on a time-of-flight PET\u002FCT system (2-3 minutes per bed position, covering skull base to mid-thigh).",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DIAGNOSTIC_TEST","68Ga-DOTA-CCK-FS PET\u002FCT","For 68Ga-DOTA-CCK-FS, imaging begins 60±5 minutes post-injection to evaluate cholecystokinin receptor (CCK-R) expression, using a time-of-flight PET\u002FCT system with low-dose CT (120 kVp, 30-50 mAs) for attenuation correction followed by whole-body PET acquisition (2-3 min\u002Fbed position). Images are reconstructed using OSEM algorithms.",[14,9],null,[25],{"name":26,"affiliation":5,"role":27},"Yaping LUO","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":23,"email":33},"Yaping Luo, MD","CONTACT","86-010-69154716","luoyaping@live.com",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":51,"phoneExt":23,"email":52},"Jiayue Li","86-010-69156874","xs@abscd.com",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","Luo Yaping","Medical Doctor (M.D.), Chief Physician, Professor, Assistant Director",[58],{"name":5,"class":6},"100603607","research-on-the-application-of-68ga-dota-cck-fs-petct-in-mtc-100603607",false,"NCT07138716","Research on the Application of 68Ga-DOTA-CCK-FS PET\u002FCT in MTC","Application Study of 68Ga-DOTA-CCK-FS PET\u002FCT in Medullary Thyroid Carcinoma (MTC) and Various Other Tumors With Positive Expression of Cholecystokinin-2 Receptor (CCK-2R)","Inclusion Criteria:\n\n1. Age not limited (male or female).\n2. Diagnosis:Confirmed or suspected medullary thyroid carcinoma (MTC) based on:\n\n   Fine-needle aspiration (FNA) cytology\u002Fhistopathology, or Elevated serum calcitonin\u002FCEA with thyroid nodule(s), or Clinical\u002Fhereditary suspicion (e.g., MEN2 syndrome), or Other histologically confirmed CCK-2R-positive tumors (e.g., neuroendocrine tumors, gastric\u002Fovarian cancers).\n3. Performance Status: Life expectancy ≥12 weeks.\n4. Contraception: Willingness to use effective birth control (if applicable).\n5. Consent: Signed informed consent and compliance with follow-up.\n\nExclusion Criteria:\n\n1. Severe hepatic\u002Frenal dysfunction (e.g., ALT\u002FAST \\>3×ULN, Cr \\>2.0 mg\u002FdL).\n2. Pregnancy\u002Flactation or planned pregnancy during the study.\n3. Inability to lie still for PET\u002FCT (e.g., severe claustrophobia).\n4. Concurrent conditions compromising study safety (investigator's judgment).\n\n\\*Note: CCK-2R positivity may be confirmed via prior immunohistochemistry (if available) or inferred from tumor type (e.g., MTC).\\*",true,"ALL",{"count":69,"type":70},30,"ESTIMATED","INTERVENTIONAL",[73],"NA","This study explores the clinical application of 68Ga-DOTA-CCK-FS PET\u002FCT in detecting cholecystokinin-2 receptor (CCK-2R)-positive tumors, particularly medullary thyroid cancer (MTC) and other malignancies. Led by Prof. Luo Yaping (PUMCH Nuclear Medicine) and Prof. Liu Zhibo (Peking University, radiochemistry expert), the trial will enroll 30-40 patients to compare 68Ga-DOTA-CCK-FS imaging with standard PET\u002FCT (e.g., 18F-FDG or 68Ga-DOTATATE). The novel tracer shows higher tumor uptake and retention in preclinical studies, potentially improving diagnosis and treatment guidance for aggressive, CCK-2R-expressing cancers. The study leverages PUMCH's Class IV Radioactive Drug License for advanced radiopharmaceutical development. Risks are minimal (diagnostic radiation dose only), and participants receive free imaging assessments. Results aim to refine precision diagnostics for MTC and related tumors.",[76],"Medullary Thyroid Carcinoma",[78,79,80],"MTC","CCK-2R","PET\u002FCT","2025-08-22",{"date":83,"type":84},"2025-08-24","ACTUAL",{"date":86,"type":84},"2025-05-10",{"date":88,"type":70},"2028-12-01",{"name":55,"class":6},1]